跳至主要内容
临床试验/NCT01828619
NCT01828619Unknown不适用

The Study of New RIC Regimen of BuFlu in Older or Intolerable Patients With Hematologic Malignant Diseases

Peking University People's Hospital1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2013年2月最近更新:
适应症

试验速览

阶段
不适用
入组人数
60
试验地点
1
主要终点
stem cell engraftment

研究概览

简要总结

The purpose of this study is to determine whether the new RIC regimen, containing of low dose of Bu (9.6mg/kg)and fludarabine without ATG, is suitable and effective in treating aged and/or intolerable patients with hematologic malignant disease, who undergoes allogenic stem cell transplantation.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Prospective

入排标准

年龄范围
55 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • diagnosed of hematologic malignant disease
  • will undergo HLA matced HSCT
  • age >=55years
  • <55year and intolerable to standard myeloablative conditioning

排除标准

  • KPS status <70
  • cardiac EF<50%
  • creatine clearance <50 ml/min
  • ALT more than 10 times of upper normal limit

结局指标

主要结局

stem cell engraftment

时间窗: 30day post transplantation

次要结局

  • toxicity and treatment related mortality(100day and 1 year post transplantation)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

FENGRONG WANG

Department of Hematology

Peking University People's Hospital

研究点 (1)

Loading locations...

相似试验